Showing results (31-40 of 782) with videos related to
Sort By:
Pageof 79
The Lancet. HIV|September 15, 2015
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS StudyJuan G Sierra-Madero, Susan Ellenberg, Mohammed S Rassool, et al.The Lancet. HIV|November 2, 2015
Recruiting male partners for couple HIV testing and counselling in Malawi's option B+ programme: an unblinded randomised controlled trialNora E Rosenberg, Tiwonge K Mtande, Friday Saidi, et al.The Lancet. HIV|November 2, 2015
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort studyCarina Cesar, Cathy A Jenkins, Bryan E Shepherd, et al.The Lancet. HIV|May 10, 2019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialHans-Jürgen Stellbrink, José R Arribas, Jeffrey L Stephens, et al.The Lancet. HIV|May 1, 2019
Potential for additional government spending on HIV/AIDS in 137 low-income and middle-income countries: an economic modelling studyAnnie Haakenstad, Mark W Moses, Tianchan Tao, et al.The Lancet. HIV|July 28, 2018
90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2Geoffrey S Gottlieb, Dana N Raugi, Robert A SmithThe Lancet. HIV|May 10, 2018
Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?Stephanie Shiau, Elaine J Abrams, Stephen M Arpadi, et al.The Lancet. HIV|October 25, 2021
HIV care continuum interventions for Black men who have sex with men in the USAHilary Goldhammer, Kenneth H Mayer, Linda G Marc, et al.The Lancet. HIV|October 14, 2021
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority studyHans Jaeger, Edgar T Overton, Gary Richmond, et al.The Lancet. HIV|April 25, 2022
Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan AfricaPageof 79